Partners

The fastest non-invasive cardiac mapping system on the market, ACORYS MAPPING SYSTEM, from Corify Care, obtains CE certification under the MDR

Esta certificación significa que el sistema ACORYS MAPPING SYSTEM cumple con los altos estándares de seguridad, salud y protección ambiental requeridos para dispositivos médicos en la Unión Europea.

Sistema ACORYS MAPPING SYSTEM desarrollado por Corify Care
Healthcare

Corify Care, a pioneering start-up based in Spain, has recently obtained the CE Mark for its innovative cardiac mapping system ACORYS under the new Medical Device Regulation (MDR). This certification signifies that the ACORYS MAPPING SYSTEM meets the high safety, health, and environmental protection standards required for medical devices in the European Union.

Andreu Climent, Co-Founder and CEO of Corify Care, stated, "Achieving the CE Mark is a significant milestone for Corify Care. It validates our commitment to providing innovative, non-invasive solutions for cardiac arrhythmias. We are excited to bring the ACORYS MAPPING SYSTEM to hospitals across Europe and improve patient outcomes." 

What is the ACORYS MAPPING SYSTEM?

The ACORYS MAPPING SYSTEM is an advanced non-invasive cardiac mapping technology that visualizes the heart's electrical activity in under 10 minutes, eliminating the need for CT or MRI scans. By utilizing body surface potential measurements and a 3D torso model, ACORYS generates highly detailed electroanatomical maps of the heart. This cutting-edge system enables clinicians to observe the heart's electrical activity in real-time, enhancing their ability to diagnose and treat cardiac arrhythmias with unparalleled precision, speed, and safety.

Impact of CE Mark Certification

With the CE Mark, the ACORYS MAPPING SYSTEM is now approved for commercial sale throughout the European Union. Hospitals and cardiac care centers can now utilize this cutting-edge technology to provide patients with precise and rapid cardiac mapping, improving the diagnosis and treatment of various arrhythmias, including atrial fibrillation and ventricular tachycardia.

Felipe Atienza, Co-founder and Chief Medical Officer, emphasizes the clinical impact: "For a clinician, being able to see what is happening in the heart before introducing catheters, and then guide those catheters during the procedure, allows us to be faster, more precise, and more effective. This capability significantly enhances our ability to treat cardiac arrhythmias efficiently and with greater accuracy." 

Benefits of the ACORYS MAPPING SYSTEM

Cardiac arrhythmias, such as atrial fibrillation, affect millions of people worldwide, leading to significant health risks, including stroke and heart failure. Traditional methods of cardiac mapping are often invasive, time-consuming, and uncomfortable for patients. The ACORYS MAPPING SYSTEM addresses these issues by providing a non-invasive, rapid, and accurate method for mapping the heart's electrical activity.

This innovative system offers several benefits:

  • Speed and Precision: Produces detailed heart maps in real-time, facilitating quick and accurate clinical decisions.
  • Non-Invasive: Allow the clinicians to see the electrical activity in the heart in those cases when invasive procedures are not an option (e.g., cardiac resynchronization therapy, cardiac activity assessment in regular consultation, etc.). When invasive mapping is available, the intervention is much more efficient thanks to the combined used of invasive and non-invasive mapping.
  • Comprehensive Analysis: Capable of generating new maps with each heartbeat, allowing continuous monitoring and detailed analysis.

About Corify Care and European Innovation Ecosystem's Support

Founded in 2019 as a spin-off from the Hospital Gregorio Marañón in Madrid and the Universitat Politècnica de València, Corify Care is dedicated to revolutionizing cardiac care through innovative technology. With a team of over 20 professionals, the company's mission is to enhance the diagnosis and treatment of cardiac arrhythmias, ultimately improving patient quality of life. In its early stages, foundational programs such as Health-Start and CaixaImpulse by Fundación La Caixa, supported by EIT Health, were crucial. In fact, in 2020, EIT Health recognized Corify's technology as the most innovative in Europe. Since 2022, EIT Health has been an integral part of the company's journey, funding the SAVE-COR project with over €2.5 million. 

In 2021, Corify took another significant leap forward with a €2.3 million investment round where Clave Capital and the Mondragón Group invested in this technology. These strategic partnerships have been essential in driving Corify Care's development and market readiness, ensuring that the ACORYS MAPPING SYSTEM can reach its full potential in improving cardiac care, achieving the CE Mark certification and being used in several clinical studies, conducted in leading hospitals in Spain and Portugal. These studies have enrolled more than 1,000 patients, which are demonstrating the critical need for this innovative technology.

María Guillem, Co-Founder and Chief Scientific Officer at Corify Care, reflects on the journey: "Fifteen years ago, this technology was little more than laboratory prototypes that required hours or even days to process a cardiac map. Today, thanks to relentless innovation and dedication, we have developed a device that can show clinicians real-time, non-invasive insights into cardiac activity." She adds, "Transforming such a complex technology into a practical, everyday tool for clinicians has been a remarkable achievement. Our team’s passion and commitment have been essential in turning this vision into reality." 

Future Prospects

With the CE Mark, Corify Care is set to expand its market presence across Europe, aiming to integrate the ACORYS MAPPING SYSTEM into clinical practice worldwide. The next steps include obtaining FDA approval in the United States and expanding to other international markets. Corify Care is committed to continuous innovation, with plans to develop ACORYS 2.0, incorporating digital twins and new clinical applications.